PH21989A - Two phase formulation comprising nifedipine - Google Patents

Two phase formulation comprising nifedipine

Info

Publication number
PH21989A
PH21989A PH30694A PH30694A PH21989A PH 21989 A PH21989 A PH 21989A PH 30694 A PH30694 A PH 30694A PH 30694 A PH30694 A PH 30694A PH 21989 A PH21989 A PH 21989A
Authority
PH
Philippines
Prior art keywords
nifedipine
phase formulation
crystalline
solid
administering
Prior art date
Application number
PH30694A
Other languages
English (en)
Inventor
Hegasy Ahmed
Rupp Roland
Ramsch Klaus-Dieter
Luchtenberg Helmut
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6199643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH21989(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PH21989A publication Critical patent/PH21989A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compounds Of Unknown Constitution (AREA)
PH30694A 1983-05-21 1984-05-18 Two phase formulation comprising nifedipine PH21989A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833318649 DE3318649A1 (de) 1983-05-21 1983-05-21 Zweiphasenformulierung

Publications (1)

Publication Number Publication Date
PH21989A true PH21989A (en) 1988-05-02

Family

ID=6199643

Family Applications (1)

Application Number Title Priority Date Filing Date
PH30694A PH21989A (en) 1983-05-21 1984-05-18 Two phase formulation comprising nifedipine

Country Status (29)

Country Link
US (1) US4562069A (pl)
EP (1) EP0126379B1 (pl)
JP (1) JPS59222475A (pl)
AT (2) ATE42198T1 (pl)
AU (1) AU564263B2 (pl)
BE (1) BE899691A (pl)
CA (1) CA1228550A (pl)
CH (1) CH658190A5 (pl)
CS (1) CS250663B2 (pl)
DD (1) DD222495A5 (pl)
DE (2) DE3318649A1 (pl)
DK (1) DK163278C (pl)
ES (1) ES8505817A1 (pl)
FI (1) FI82376C (pl)
FR (1) FR2550092B1 (pl)
GB (1) GB2139892B (pl)
GR (1) GR82018B (pl)
HK (1) HK63789A (pl)
HU (1) HU193287B (pl)
IL (1) IL71871A (pl)
IT (1) IT1218848B (pl)
KE (1) KE3889A (pl)
NO (1) NO164817C (pl)
NZ (1) NZ208214A (pl)
PH (1) PH21989A (pl)
PL (1) PL142890B1 (pl)
PT (1) PT78611B (pl)
SG (1) SG36089G (pl)
ZA (1) ZA843769B (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
US4740365A (en) * 1984-04-09 1988-04-26 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
DE3424553A1 (de) * 1984-07-04 1986-01-09 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
DE3639073A1 (de) * 1986-11-14 1988-05-26 Klinge Co Chem Pharm Fab Feste arzneizubereitungen und verfahren zu ihrer herstellung
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4954346A (en) * 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
DE4130173A1 (de) * 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
MX9801835A (es) 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
EP0852141A1 (en) * 1996-08-16 1998-07-08 J.B. Chemicals & Pharmaceuticals Ltd. Nifedipine containing pharmaceutical extended release composition and a process for the preparation thereof
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
IN186245B (pl) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
CN1228043C (zh) * 1999-09-30 2005-11-23 爱德华·孟岱尔股份有限公司 用于高溶解度药物的缓释基质
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2002334987A1 (en) * 2001-10-15 2003-04-28 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
EP1471887B1 (en) 2002-02-04 2010-04-21 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
EP2755637B1 (en) * 2011-09-13 2020-08-12 ISP Investments LLC Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer
US20130259931A1 (en) * 2012-03-30 2013-10-03 Bandi Parthasaradhi Reddy Oral pharmaceutical compositions of nebivolol and process for their preparation
US8313774B1 (en) * 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
JPS5446837A (en) * 1977-09-19 1979-04-13 Kanebo Ltd Easily absorbable nifedipin composition, its preparation, and anti-stenocardia containing the same
EP0012523B2 (en) * 1978-11-20 1988-02-03 American Home Products Corporation Therapeutic compositions with enhanced bioavailability and process for their preparation
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS56110612A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS5668619A (en) * 1980-10-09 1981-06-09 Yamanouchi Pharmaceut Co Ltd Nifedipine-containing solid composition
JPS5785316A (en) * 1980-11-14 1982-05-28 Kanebo Ltd Preparation of easily absorbable nifedipine preparation
JPS57167911A (en) * 1981-04-09 1982-10-16 Kyoto Yakuhin Kogyo Kk Liquid pharmaceutical of nifedipine
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
DE3142853A1 (de) * 1981-10-29 1983-05-11 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit nifedipin und verfahren zu ihrer herstellung
EP0078430B2 (de) * 1981-10-29 1993-02-10 Bayer Ag Verfahren zur Herstellung von festen, schnellfreisetzenden Arzneizubereitungen mit Dihydropyridinen
JPS5877811A (ja) * 1981-11-04 1983-05-11 Kanebo Ltd 安定な易吸収性ニフエジピン製剤の製法

Also Published As

Publication number Publication date
ZA843769B (en) 1984-12-24
ES532515A0 (es) 1985-06-16
CA1228550A (en) 1987-10-27
NO841838L (no) 1984-11-22
FI841995L (fi) 1984-11-22
PT78611A (en) 1984-06-01
GR82018B (pl) 1984-12-12
EP0126379A2 (de) 1984-11-28
IL71871A0 (en) 1984-09-30
DK247284A (da) 1984-11-22
FR2550092B1 (fr) 1987-11-20
DE3477733D1 (en) 1989-05-24
NZ208214A (en) 1986-10-08
ATE42198T1 (de) 1989-05-15
US4562069A (en) 1985-12-31
CS250663B2 (en) 1987-05-14
NO164817B (no) 1990-08-13
FI82376B (fi) 1990-11-30
IT8421013A0 (it) 1984-05-18
ES8505817A1 (es) 1985-06-16
DK247284D0 (da) 1984-05-17
AT390879B (de) 1990-07-10
PT78611B (en) 1986-07-15
NO164817C (no) 1990-12-19
BE899691A (fr) 1984-11-19
GB8412820D0 (en) 1984-06-27
IL71871A (en) 1987-07-31
JPS59222475A (ja) 1984-12-14
KE3889A (en) 1989-09-01
DD222495A5 (de) 1985-05-22
HK63789A (en) 1989-08-18
EP0126379B1 (de) 1989-04-19
AU2806084A (en) 1984-11-22
HU193287B (en) 1987-09-28
EP0126379A3 (en) 1986-07-09
FI82376C (fi) 1991-03-11
CH658190A5 (de) 1986-10-31
SG36089G (en) 1989-10-13
DK163278C (da) 1992-09-07
IT1218848B (it) 1990-04-24
HUT34690A (en) 1985-04-28
AU564263B2 (en) 1987-08-06
DK163278B (da) 1992-02-17
GB2139892B (en) 1987-04-23
FR2550092A1 (fr) 1985-02-08
FI841995A0 (fi) 1984-05-17
GB2139892A (en) 1984-11-21
ATA164884A (de) 1990-01-15
PL247744A1 (en) 1985-11-05
DE3318649A1 (de) 1984-11-22
PL142890B1 (en) 1987-12-31

Similar Documents

Publication Publication Date Title
PH21989A (en) Two phase formulation comprising nifedipine
PT84786A (en) Process for the preparation of pharmaceutical formulations of acid labile substances for oral use
ZA894128B (en) Use of gamma-hydroxybutryic acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism,and the compositions obtained
NZ221962A (en) Oral pharmaceutical compositions comprising a mixture of ibuprofen and aluminium hydroxide and process for their preparation
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
NZ225950A (en) Calcium citrate malate in the molar ratio of 6:2:3; pharmaceutical compositions
DK541189D0 (da) Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af interstitiel cystitis
ES8505379A1 (es) Un metodo de fabricar 1, 4-dihidropiridina-3-carboxilatos
IL84168A0 (en) Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
JPS6422A (en) Prophylactic and remedy for hypocalcemia and bone catabolism
FR2653662B1 (fr) Application du n-methyl (pyridyl-3)-2 tetrahydrothiopyranne-carbothioamide-2-oxyde-1 a la preparation de medicaments destines au traitement de l'insuffisance coronarienne.
DE69313534D1 (de) Digitoxigenin und Dihydrodigitoxigenin 3-beta-Derivate und pharmazeutische Präparate davon, zur Behandlung von hypertonie
ZA876116B (en) Pharmaceutical preparation for administration by percutaneous absorption and method for its manufacture
FR2592653A1 (fr) Derives de chromene, procede d'obtention et compositions pharmaceutiques.